Клиническое значение экспрессии рецептора эпидермального фактора роста при раке молочной железы, яичников, толстой кишки и легкого
Диссертация
Современная химиотерапия основана на комбинированном применении целого ряда препаратов с различным механизмом действия на опухолевые клетки. Однако, в ряде случаев опухоли оказываются нечувствительными к проводимому лечению или становятся к нему резистентными. Это определяет актуальность активного поиска новых эффективных противоопухолевых препаратов, основанных на принципиально новых механизмах… Читать ещё >
Список литературы
- Герштейн Е. С. Кушлинский Н.Е. Изучение механизмов передачи митогенных сигналов факторов роста как основа для создания и использования новых противоопухолевых препаратов. // В сб. Трудов: Новое в онкологии. 1998. — вып. № 3. — С. 126−149.
- Кушлинский Н.Е. Клинические перспективы исследования рецепторов эпидермального фактора роста в опухолях человека. // Кли-нич. лаб. диагностика. 1996. — № 1. — С. 9−12.
- Полоцкий Б.Е., Кушлинский Н. Е., Герштейн Е. С., Дыхно А. Ю., Костылева О. И. Рецепторы эпидермального фактора роста и их лиганды при немелкоклеточном раке легкого. // Вестн. Рос. АМН. -1998.-№ 5. -С. 51−54.
- Летягин В.П. Значение рецепторов эпидермального фактора роста в опухолях больных распространенным раком молочной железы. // Актуальные вопросы маммологии. 1998. — С. 107.
- Герштейн Е.С. Перспективы исследования молекулярно-биологических особенностей рака молочной железы в клинике. // Вопр. биол. мед. и фармац. химии. 1998. — № 3. — С. 3−10.
- Кушлинский Н.Е. Рецепторы эпидермального фактора роста при раке молочной железы: от эксперимента к клинике. // Бюл. экспе-рим. биологии и медицины. 1998. — Т. 126. — № 11. — С. 485−496.
- Огнерубов Н.А., Кушлинский Н. Е., Летягин В. П., Андросова Л. А., Герштейн Е. С. Взаимосвязь экспрессии рецепторов эпидермального фактора роста с клинико-морфологическими особенностями рака молочной железы. // Новое в онкологии. 1998. — Вып. 3. — С. 8791.
- Герштейн Е.С. Изучение механизмов передачи митогенных сигналов факторов роста как основа для создания и использования новых противоопухолевых препаратов. // Вопр. биол. мед. и фар-мац. Химии. 1999. — № 2. — С. 3−12.
- Тюляндин С.А. Немелкоклеточный рак легкого в 2004 году: високосный год. // Практическая Онкология. 2005. — № 21.
- Герштейн Е.С., Бассалык Л. С., Летягин В. П. Клиническое значение исследования рецепторов эпидермального фактора роста при раке молочной железы. // Вопросы онкологии. 1994. — Т. 40. — № 7.12.-С. 266−275.
- Gershstein E.S., Kushlinsky N.E. // Eur J Cancer. 2000. — Vol. 36. -Suppl. 5. — P. S109. -Abs. 330.
- Chantry A. The kinase domain and membrane localization determine intracellular interactions between epidermal growth factor receptors. // J. Biol. Chem., 1995. — Vol. 270. — P. 3068−3073.
- Dougall W.C., Qian X., Peterson N.C. et al. The neu oncogene, signal transduction pathways, transformation mechanisms and evolving therapies. // Oncogene. 1994. — Vol. 9. — P. 2109−2123.
- Hanks S.K., Quinn A.M., Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. // Science. 1988. — Vol. 241. — P. 42−52.
- Margolis В., Skolnic E.Y. Activation of Ras by receptor tyrosine kinases. //J. Am. Soc. Nephrol. 1994. — Vol. 5. — P. 1288−1299.
- Reese D.M., Slamon D.J. HER-2/neu signal transduction in human breast and ovarian cancer. // Stemm Cells. 1997. — Vol. 15. — P. 1−8.
- Schlessinger J. The epidermal growth factor receptor as a multifunctional allosteric protein. // Biochemistry. 1988. — Vol. 27. — P. 31 193 123.
- Velu T J. Structure, function and transforming potential of the epidermal groth factor receptor. // Mol. Cell Endocrinol. 1990. — Vol. 70. -P. 205−16.
- Okabayashi Y., Kido Y., Okutani T. et al. Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of She in intact cells. // J. Biol. Chem. 1994. — Vol. 269. — P. 2134−2141.
- Paci A., Ciarimboli G., Ferdeghini M. Fattori di crescita ed oncogeni nello sviluppo e nella carcinogenesi. // Minerva Med. 1994. — Vol. 85. — P. 467−490.
- Hernandes-Sotomayor S.M.T., Carpenter G. Epidermal growth factor receptor: elements of intracellular communication. // J. Membr. Biol. -1992.-Vol. 128.-P. 81−9.
- Kellof G.J., Fay J.R., Steele V.E. et al. Epidermal growth factor receptor kinase inhibitors as potential cancer chemopreventives. // Cancer Epidemiol. Biomarkers Prev. — 1996. — Vol. 5. — P. 657−66.
- Davies D.E., Chamberlin S.G. Targeting the epidermal growth factor receptor for therapy of carcinomas. // Biochem Pharmacol. 1996. -Vol. 51.-P. 1101−10.
- Fry D.W. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. // Pharmacol. Ther. 1999. -Vol. 82 (2−3).-P. 207−18.
- Bridges A.J. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. // Curr. Med. Chem. 1999. — Vol. 6. -P. 825−43.
- Todderud G., Carpenter G. Epidermal growth factor: the receptor and its function. // BioFactors. 1989. — Vol. 2. — P. 11−15.
- Woodburn J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. // Phannacol. Ther. 1999. — Vol. 82. — P. 24 150.
- Perrotte P., Matsumoto Т., Inoue K., et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. // Clin. Cancer Res. 1999. — Vol. 5. — P. 257−264.
- Kulik G., Klippel A., Weber M.J. Antiapoptotic signaling by the insulin-like growth factori receptor, phosphatidylinositol 3-kinase, and Akt. // Mol. Cell Biol. 1997. — Vol. 17. — P. 1595−606.
- Moyer J.D., Barbacci E.G., Iwata K.K. et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. // Cancer Res. 1997. — Vol. 57. — P. 4838−48.
- Karnes Jr. W.E., Weller S.G., Adjei P.N. et al. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. // Gastroenterology. 1998. — Vol. 114. — P. 930−9.
- Wu X., Fan Z., Masui H. et al. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. // J. Clin. Invest. 1995. -Vol. 95.-P. 1897−905.
- Klijn J.G.M., Berns P.M.J.J., Schmitz P.I.M. et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breastcancer: a review on 5232 patients. // Endocr. Rev. 1992. — Vol. 13. — P. 3−17.
- Rajkumar Т., Gullick W.J. The type I growth factor receptors in human breast cancer. // Breast Cancer Res. Treat. 1994. — Vol. 29. — P. 3−9.
- Bucci В., D’Agnano I., Botti C. et al. EGF-R expression in ductal breast cancer: proliferation and prognostic implications. // Anticancer Res. 1997. — Vol. 17. — P. 769−74.
- Klijn J.G., Look M.P., Portengen H. et al. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. // Breast Cancer Res. Treat. 1994. — Vol. 29.-P. 73−83.
- Bartlett J.M., Langdon S.P., Simpson B.J. et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. // Br. J. Cancer. 1996. — Vol. 73. — P. 301−6.
- Meden H., Marx D., Raab T. et al. EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. // J. Obstet. Gynaecol. 1995. — Vol. 21. — P. 167−78.
- Baselga J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. // J. Clin. Oncol. -2000. Vol. 18.-P. 904−914.
- Rubin, M.S. Monoclonal antibody IMC-C225, an anti-epidermal growth factor receptor, for patients with EGFR-positive tumors refractory to or in relapse from previous therapeutic regimens. // Proc. Am. Soc. Clin. Oncol. 2000. — Vol. 19. — P. 474a.
- Robert F. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. // J. Clin. Oncol. 2001. — Vol. 19. — P. 3234−3243.
- Abbruzzese J.L. Phase II study of anti-epidermal growth factor receptor antibody cetuximab in combination with gemcitabine in patients with advanced pancreatic cancer. // Proc. Am. Soc. Clin. Oncol. 2001. — Vol. 20. — Abs. 130a.
- Saltz L. Cetuximab plus irinotecan is active in CPT-11-refractory colorectal cancer that expresses epidermal growth factor receptor. // Proc. Am. Soc. Clin.-2001.-Vol. 20.-Abs. 3a.
- Negoro S., Nakagawa K. Final results of a phase I intermittent dose -escalation trial of ZD 1839 (Iressa) in Japanese patients with various solid tumors. // Proc. Am. Soc. Clin. Oncol. 2001. — Abs. 1292.
- Goss G.D., Hirte H. Final results of the dose escalation phase of a phase I pharmacokinetics (PK), pharmacodinamic (PD) and biological activity study of ZD1839: NCIC CTG IND.122. // Proc. Am. Soc. Clin. Oncol.-2001.- Abs. 335.
- Fukuoka M., Yano S., Giaccone G. Final results from a phase II trial of ZD1839 for patients with advanced non-small-cell lung cancer (IDEAL I). // Proc. Am. Soc. Clin. Oncol. 2002. — Abs. 1188.
- Kris M.G., Natale R.B., Herbst R.S. A phase II trial of ZD1839 in advanced non-small-cell lung cancer patients who had failed platinum-and docetaxel-based regimens (IDEAL 2). // Proc. Am. Soc. Clin. Oncol. -2002. Abs. 1166.
- Karp D.D., Silberman S.L., Csudae R. Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358, 774 in patients with advanced solid tumors. // Proc. Am. Soc. Clin. Oncol. 1999. — Vol. 18. — P. 388.
- Senzer N.N., Soulieres D., Siu L. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. // Proc. Am. Soc. Clin. Oncol. 2001. — Vol. 21. — P. 2.
- Finkier N., Gordon A., Crozier M. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. // Proc. Am. Soc. Clin. Oncol. 2001. — Vol. 21. — P. 208.
- Perez-Soler R., Chachoua A., Hammond L.A. et al. Determinants of tumor response and survival with Erlotinib in patients with non-small-cell lung cancer. // J. Clin. Oncol. 2004. — Vol. 22. — P. 3238−3247.
- Mendelsohn J., Fan Z. Epidermal growth factor receptor family and chemosensitization. // J. Natl. Cancer Inst. (Bethesda). 1997. — Vol. 89.-P. 341−343.
- Ryan P.D., Chabner B.A. On receptor inhibitors and chemotherapy. // Clin. Cancer Res. 2000. — Vol. 6. — P. 4607−4609.
- Lynch T.J., Lilenbaum R., Bonomi P. et al. // Proc. Am. Soc. Clin. Oncol. 2004. — Vol. 23. — Abs. 7084. — P. 634.
- Rosell R., Daniel C., Ramlau A. et al. // Proc. Am. Soc. Clin. Oncol.2004. Vol. 23. — Abs. 7012. — P. 618.
- Saltz L.B., Metropol N.J., Loehrer P.J. et al. Phase II trial of Cetuximab in patients with refractory colorectal cancer that expresses the Epidermal Growth Factor Receptor. // J. Clin. Oncol. 2004. — Vol. 22. -P. 1201−1208.
- Tabernero J., Van Cutsem E., Sastre J. et al. // Proc. Am. Soc. Clin. Oncol. 2004. — Vol. 23. — Abs. 3512. — P. 248.
- Lenz H-J., Mayer R.J., Gold P. et al. // Proc. Am. Soc. Clin. Oncol. -2004.-Vol. 23. Abs. 3510. — P. 248.
- Chung K.Y., Schia J., Kemeny N.E., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the Epidermal Growth Factor Receptor by immunohistochemistry. // J. Clin. Oncol. 2005. — Vol. 23. — P. 1−8.
- Burtness B.A., Li Yi, Flood W. et al. Phase 3 trial comparing cis-platin+placebo+anti epidermal growth factor antibody C225 in patients with metastatic/recurrant head&neck cancer. // Proc. Am. Soc. Clin. Oncol. 2002. — Vol. 21. — Abs. 901.
- Mendelsohn J., Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. // J. Clin. Oncol.2003. Vol. 21. — No. 14. — P. 2787−2799.
- Negoro S., Nakagawa K. Final results of a phase I intermittent dose-escalation trial of ZD1839 (Iressa) in Japanese patients with various solid tumors. // Ann. Of One. 2003. — Vol. 14. — 922−930.
- Ochs J., Grous J.J., Warner K.L. // Proc. Am. Soc. Clin. Oncol.2004. Vol. 23. — Abs. 7060. — P. 628.
- Reiling R., Wade J., Govindan R. et al. // Proc. Am. Soc. Clin. Oncol. 2004. — Vol. 23. — Abs. 7087. — P. 635.
- West H., Franklin W.A., Gumerlock P.H. et al. // Proc. Am. Soc. Clin. Oncol. 2004. — Vol. 23. — Abs. 7014.-P. 618.
- Ezra E.W., Cohen F.R. Phase 2 trial of ZD1839 in recurrant or metastatic squamous cell carcinoma of the head and neck. // J. Clin. Oncol. — 2003,-Vol. 21.-No. 10. -P. 1980−1987.
- Baselga J., Albanell J., Ruiz A. et al. Phase II and tumor pharmacodynamic study of gefitinib (ZD 1839) in patients with advanced breast cancer. // Proc. Am. Soc. Clin. Oncol. 2003. — Vol. 22. — Abs. 24. — P. 7.
- Fisher G.A., Kuo Т., Cho C.D. et al. // Proc. Am. Soc. Clin. Oncol. -2004. Vol. 23. — Abs. 3514. — P. 249.
- Giaconne G., Herbst R.S., Manegold C. et al. Gefitinib in combination with Gemcitabine and Cisplatin in advanced non-small-cell lung cancer: a phase III trial INTACT I. // J. Clin. Oncol. — 2004. — Vol. 22. -P. 777−784.
- Herbst R.S., Giaconne G., Schiller J. et al. Gefitinib in combination with Paclitaxel and Carboplatin in advanced non-small-cell lung cancer: a phase III trial INTACT 2. // J. Clin. Oncol. — 2004. — Vol. 22. — P. 785−794.
- Piperdi В., Perez-Soler R. The role of EGFR-tyrosine kinase inhibitors in cancer. // Signal. 2003. — Vol. 4. — P. 4−8.
- Shepherd F.A., Pereira J., Ciuleanu Т.Е. et al. // Proc. Am. Soc. Clin. Oncol. Late-Breaking Abstract Booklet. 2004. — Vol. 18. — Abs. 7022.
- Herbst R.S., Prager D., Hermann R. et al. // Proc. Am. Soc. Clin. Oncol. 2004. — Vol. 23. — Abs. 7011. — P. 617.
- Gatzemeier U., Pluzanska A., Szczesna A. et al. // Proc. Am. Soc. Clin. Oncol. -2004. Vol. 23. — Abs. 7010. — P. 617.
- Atalay G., Cardoso F. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. // Ann. Of One. 2003. — Vol. 14. — P. 13 461 363.
- Lynch T.J., Bell D.W., Sordella R. et al. // N. Engl. J. Med. 2004. -Vol. 350.-P. 2129−39.
- Paez J.G., Janne P.A., Lee J.C. et al. // Science. 2004. — Vol. 304. -P. 1497−5000.
- Han S.-W., Kim T.-Y., Hwang P. G. et al. Predictive and prognostic impact of Epidermal Growth Factor Receptor mutation in non-small-cell lung cancer patients treated with Gefitinib. // J. Clin. Oncol. 2005. -Vol. 23.-P. 1−9.
- Dickstein В., Valverius E.M., Wosikowski K. et al. Increased epidermal growth factor receptor in estrogen-responsive, adriamycin-resistant MCF-7 cell line. // J. Cell Physiol. 1993. — Vol. 157. — P. 110−8.
- Kroning R., Jones J. A., Horn D.K. et al. Enhancement of drug sensitivity of human malignancies by epidermal growth factor. // Br. J. Cancer. 1995. — Vol. 72. — P. 615−9.
- Mendelsohn J., Fan Z. // J. Natl. Cancer Inst. 1997. Vol. 89. — P. 341−3.
- Ryan P.D., Chabner B.A. // Clin. Cancer Res. 2000. — Vol. 6. — P. 4607−9.
- Harari P.M., Huang S.M. // Clin. Cancer Res. 2000. — Vol. 6. — P. 323−5.
- Salomon D.S., Brandt R., Ciardiello F. et al. // Crit. Rev. Oncol. He-matol.- 1995.-Vol. 19.-P. 183−232.
- Hutcheson I.R., Gee J.M.W., Barrow D. et al. // Presented at the Signal Transduction Pathways and Regulation of Gene Expression as Therapeutic Targets Conference, Kitchberg, Luxembourg. 2000.
- Akimoto Т., Hunter N.R., Buchmiller L. et al. // Clin. Cancer Res. -1999. Vol. 5. — P. 2884−90.
- Wosikowski K., Schuurhuis D., Kops G.J. et al. // Clin. Cancer Res. -1997.-Vol. 3.-P. 2405−14.
- Walker R.A., Dearing S.J. // Breast Cancer Res. Treat. 1999. — Vol. 53.-P. 167−76.
- Sainsbury J.R., Farndon J.R., Sherbet G.V. et al. // Lancet. 1985. -Vol. l.-P. 364−6.
- Sainsbury J.R., Farndon J.R., Needham G.K. et al. // Lancet. 1987. -Vol. l.-P. 1398−402.
- Neskovic-Konstantinovic Z., Mitrovic L., Spuzic I. et al. // Eur. J. Cancer. 2000. — Vol. 36. — Suppl. 5. — Abs. 340. — P. S111.
- Klijn J.G., Bems P.M., Schmitz P.I. et al. Epidermal growth factor receptor in clinical breast cancer: update 1993. // Endocr. Rev. 1993. -Vol. l.-P. 3−6.
- Fox S.B., Leek R.D., Smith K. et al. Tumor angiogenesis in node-negative breast carcinomas relation with epidermal growth factor receptor, estrogen receptor, and survival. // Breast Cancer Res. Treat. -1994. -Vol. 29.-P. 109−116.
- Fox S.B., Smith K., Hollyer J. et al. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. // Breast Cancer Res. Treat. 1994. — Vol. 29. — P. 41−49.
- Gasparini G., Boracchi P., Bevilacqua P. et al. A multiparametric study of the prognostic value of epidermal growth factor receptor in operable breast carcinoma. // Breast Cancer Res. Treat. 1994. — Vol. 29. -P. 59−61.
- Harris A.L., Nicholson S., Sainsbury R. et al. Epidermal growth factor receptors and other oncogenes as prognostic markers. // Monogr. Natl. Cancer Inst. 1992. — Vol. 11. — P. 181−187.
- Nicholson R.I., Mclelland R.A., Gee J.M. et al. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. // Breast Cancer Res. Treat. 1994 — Vol. 29. — P. 117−125.
- Nicholson R.I., McClelland R.A., Finlay P. et al. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. // Eur. J. Cancer. 1993. -Vol. 29A. — P. 1018−1023.
- Nicholson S., Sainsbury J.R., Halcrow P. et al. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. // Lancet. 1989. — Vol. 1(8631). — P. 182−185.
- Newby J.C., Johnston S.R., Smith I.E. et al. // Clin. Cancer Res. -1997.-Vol. 3.-P. 1643−51.
- Wright C., Nicholson S., Angus B. et al. // Br. J. Cancer. 1992. -Vol. 65.-P. 118−21.
- Nicholson R.L., Hutcheson I.R., Knowlden J.M. et al. // Clin. Cancer Res. 2004. — Vol. 1. — P. 346−54S.
- Robertson J.F.R., Gutteridge E., Cheung K.L. et al. // Proc. Am. Soc. Clin. Oncol. 2003. — Vol. 22. — Abs. 23. — P. 7.
- Gutteridge E., Gee J.M., Nicholson R.L. et al. // Proc. Am. Soc. Clin. Oncol. 2004. — Vol. 38. — Abs. 648.
- Gee J.M., Harper M.E., Hutcheson I.R. et al. // Endocrinol. 2003. -Vol. 144.-P. 5105−17.
- DiGiovanna M.P., Stern D.F., Edgerton S.M. et al. Relationship of Epidermal Growth Factor Receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. // J. Clin. Oncol. 2005. -Vol. 23.-P. 1152−1160.
- Spano J.-P., Lagorce C., Atlan D. et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. // Ann. One. 2005. -Vol. 16.-P. 102−208.
- Khorana A.A., Ryan C.K., Cox. C. EGFR and VEGF expression in primary colon tumors as predictors of survival in stage II and III colon cancer. // Proc. Am. Soc. Clin. Oncol. 2002. — Abs. 2395.
- Selvaggi G., Novello S., Torri V. et al. Epidermal Growth Factor Receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. // Ann. One. 2004. — Vol. 15. — P.- 28−32.
- Herbst R.S., Shin D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors. A new paradigm for cancer therapy. // Cancer. 2002. — Vol. 94. — P. 1593−1611.
- Nicholson R.I., Gee J.M.W., Harper M.E. EGFR and cancer prognosis. //Eur. J. Cancer. -2001. Vol. 37. — P. S9-S15.
- Maurizi M., Almadori G., Ferrandina G. et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. // Br. J. Cancer. 1996. — Vol. 74. — P. 1253−1257.
- Fischer-Coibrie J., Witt A., Heinzl H. et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. // Anticancer Res. 1997. — Vol. 17. — P. 613−620.
- Kersemaekers A.M., Fleuren G.J. Oncogene alterations in carcinonas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. // Clin. Cancer Res. 1999. -Vol. 5.-P. 577−586.
- Mellon K., Wright C., Kelly P., Home C.H., Neal D.E. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. // J. Urol. 1995. — Vol. 153. — P. 919−925.
- Hirai Т., Kuwahara M., Yoshida K. et al. Clinical results of transhiatal esophagectomy for carcinoma of the lower thoracic esophagus according to biological markers. // Dis. Esophagus. 1998. — Vol. 11. — P. 221−225.
- Yonemura Y., Takamura H., Ninomiya I. et al. Interrelationship between transforming growth factor alpha and epidermal growth factor receptor in advanced gastric cancer. // Oncology. — 1992. — Vol. 49. — P. 157−161.
- Niikura H., Sasano Y., Matsunaga G. et al. Prognoctic value of epidermal growth fector receptor expression in endometrioid endometrial carcinoma. // Hum. Pathol. 1995. — Vol. 26. — P. 892−896.
- Tsugawa K., Yonemura Y., Hirono Y. et al. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancer: correlation to clinical features. // Oncology. — 1998. — Vol. 55.-P. 475−481.
- Takita M., Onda M., Tokunaga A. Immunohistochemical demonstration of angiogenic growth factors and EGF receptor in hepatic metastases and primary human gastric cancer. // Nippon Ika Daigaku Zasshi. -1998.-Vol. 65.-P. 358−366.
- Yasui W., Hata J., Yokozaki H. et al. Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma. // Int. J. Cancer. 1998. — Vol. 41. — P. 211−217.
- Yasui W., Sumiyoshhhi H., Hata J. et al. Expression of epidermal growth factor rexeptor in human gastric and colonic carcinomas. // Cancer Res. 1988. — Vol. 48.-P. 137−141.
- Prakash I., Mathur R.P., Kar P., Ranga S., Talib V.N. Comparative evaluation of cell proliferative indices and epidermal growth factor receptor expression in gastric carcinomas. // Indian J. Pathol. Microbiol. — 1997.-Vol. 40.-P. 481−490.
- Yang A., Lu X., Chen Y. The role of endoscopic ultrasonography and epidermal growth factor receptor assay in preoperative staging for gastric carcinoma. // Chung Hua Nei Ко Tsa Chih. 1995. — Vol. 34. — P. 743−746.
- Nicholson R.I., Mc Clelland R.A., Gee J.M. et al. Transforming growth factor-alpha and endocrine sensitivity in breast cancer. // Cancer Res.-1994.-Vol. 54.-P. 1684−1689.
- Kluftinger A.M., Robinson B.W., Quenville N.F., Finley R.J., Davis N.L. Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. // Surg. Oncol. 1992. — Vol. 1. — P. 97−105.
- Steele R.J., Kelly P., Ellul В., Eremin O. Epidermal growth factor receptor expression in colorectal cancer. // Br. J. Surg. 1990. — Vol. 77. -P. 1352−1354.
- Tateishi M., Ishida Т., Mitsudomi Т., Kaneko S., Sugimachi K. Im-munohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. // Cancer Res. 1990. — Vol. 50. — P. 70 777 080.